Efficacy evaluation of lafutidine for mild reflux esophagitis in Japanese patients

Journal of Japanese Society of Gastroenterology

Volumn 107, Issue 4, 2010, Pages 588-597

  Ohara, Shuichi ^a   Haruma, Ken ^b   Kinoshita, Yoshikazu ^c   Kusano, Motoyasu ^d  

^a TOHOKU ROSAI HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c SHIMANE UNIVERSITY   (Japan)

^d GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; LAFUTIDINE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; JAPANESE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; TREATMENT DURATION;

ACETAMIDES; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ESOPHAGITIS, PEPTIC; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES;

EID: 77951856391     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fujimoto K, Iwakiri R, Okamoto K, et al: Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. J Gastroenterol 38(suppl); 3-6: 2003 (Pubitemid 36442877)
2. Devault KR, Castell DO, American College of Gastroenterology : Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100; 190-200: 2005
3. Haruma K, Kamada T, Kawaguchi H, et al: Effect of age and Helicobacter pylori infection on gastric acid secretion. J gastroenterol Hepatol 15; 277-283: 2000
4. Feldman M, Cryer B, McArthur KE, et al: Effects of aging and gastritis on gastric acid and pepsin secretion in humans : a prospective study. Gastroenterology 110; 1043-1052: 1996 (Pubitemid 26113743)
5. 2 receptor antagonist than by the proton pump inhibitor lansoprazole. World J Gastroenterol 14; 2406-2410: 2008 (Pubitemid 351877614)
6. Inamori M, Togawa J, Iwasaki T, et al: Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for ondemand use? J Gastroenterol 40; 453-458: 2005 (Pubitemid 40823279)
7. Simon TJ, Berenson MM, Berlin RG. et al: Randomized, placebo-controlled comparison of famotidine 20mg b.d. or 40mg b.d. in patients with erosive oesophagitis. Aliment Pharmacol Ther 8; 71-79: 1994
8. Silver MT, Murdock RH, Morrill BB, et al: Ranitidine 3%mg twice daily and 150mg four-times daily are effective in healing erosive oesophagitis. Aliment Pharmacol Ther 10; 373-380:1996
9. Cloud ML, Enas N, Humphries TJ, The Rabeprazole Study Group, et al: Rabeprazole in the treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease (GERD). Dig Dis Sci 43; 993-1000: 1998
10. Richter JE, Bochenek W. Panatoprazole US GERD Study Group: Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol 95; 3071-3080:2000
11. Sontag SJ, Hirschowitz BI, Holt S, et al: Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. Gastroenterology 102; 109-118: 1992
12. Kusano M, lno K, Yamada T, et al: Interobserver and intraobsever variation in endoscopic assessment of GERD using the "Los Angeles" classification. Gastrointest endosc 49; 700-704: 1999
13. Nasseri-Moghaddam S, Razjouyan H, Nouraei M, et al: Inter- and intra-observer variability of the Los Angeles classification: a reassessment Arch Iran Med 10; 48-53: 2007